Bowel perforation in non-small cell lung cancer after bevacizumab therapy

By Schellhaas Elisabeth   Loddenkemper Christoph   Schmittel Alexander   Buhr Heinz-J.   Pohlen Uwe  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 184-187

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab AVAiLs in non-small cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1593, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

By Leon Luis   Vázquez Sergio   Gracia José Manuel   Casal Joaquín   Lazaro Martín   Firvida José Luis   Amenedo Margarita   Santome Lucia   Macia Sonia  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1389-1396

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues

By  

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 961-971

Bentham Science Publishers

Access to resources Recommend Favorite